Articles

Videos

Podcasts

Clinical

Semaglutide (Wegovy) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients.

Daily Medication Pearl: Semaglutide (Wegovy)

Insurers are refusing to cover new, highly effective anti-obesity drugs, but some prescribers are getting around the issue.

Calling Them “Vanity Drugs,” Some Insurers Refuse to Cover New Anti-Obesity Drugs

Contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.

Daily Medication Pearl: Naltrexone HCl and Bupropion HCl (Contrave)

Physicians often overlook those with lower BMIs who have nonalcoholic fatty liver disease and lower rates of other comorbidities, investigators say.

Study Results Show More Cardiovascular Disease in Lean Individuals With NAFLD 

Clinical trial participants who took the drug lost up to 52 lb., or 24 kg, in the 72-week, phase 3 study.

Lilly’s Tirzepatide Delivers Up to 22.5% Weight Loss in Adults Who Are Obese or Overweight

Ertugliflozin (Steglatro) is a sodium glucose co-transporter 2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Daily Medication Pearl: Ertugliflozin (Steglatro)

Psychedelic medicines like psilocybin work to re-wire the brain, potentially addressing the root cause of eating disorders rather than the symptoms.

Psilocybin-Assisted Therapy Has Potential for Treatment of Binge Eating Disorder

In a clinical trial, 86.4% of patients on semaglutide achieved a 5% weight loss at week 68 compared to 31.5% with placebo. 

Clinical Overview: Semaglutide (Wegovy) for Weight Management

Estosterone undecanoate (Tlando; Antares Pharma, Inc) is indicated as testosterone replacement therapy for conditions associated with a deficiency or absence of endogenous testosterone in adult patients.

FDA Approves Oral Testosterone Replacement Therapy for Hypogonadism

Semaglutide (Ozempic; Novo Nordisk) approved as a once-weekly subcutaneous injection for the treatment of adults with type 2 diabetes.

FDA Approves 2.0 mg Dose of Semaglutide Injection for Type 2 Diabetes

® Weight Management Resource Center is a comprehensive resource for clinical news and expert insights on issues related to chronic obesity and the associated health issues.